Teresa L Kauf

Summary

Affiliation: University of Florida
Country: USA

Publications

  1. pmc Patients' willingness to accept the risks and benefits of new treatments for chronic hepatitis C virus infection
    Teresa L Kauf
    Department of Pharmaceutical Outcomes and Policy, University of Florida, Gainesville, FL, USA
    Patient 5:265-78. 2012
  2. pmc Factors influencing the participation of gastroenterologists and hepatologists in clinical research
    Anouk T Dev
    Duke Clinical Research Institute, PO Box 17969, Durham, North Carolina, USA
    BMC Health Serv Res 8:208. 2008
  3. doi request reprint A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy
    Teresa L Kauf
    Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL 32610 0496, USA
    Value Health 11:1144-53. 2008
  4. doi request reprint Methodological concerns with economic evaluations of meningococcal vaccines
    Teresa L Kauf
    Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA
    Pharmacoeconomics 28:449-61. 2010
  5. doi request reprint Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV
    Teresa L Kauf
    University of Florida, Gainesville, Florida, USA
    Pharmacoeconomics 28:1025-39. 2010
  6. doi request reprint Cost-utility analysis of rimonabant in the treatment of obesity
    Christian Hampp
    Pharmacy Health Care Administration, College of Pharmacy, University of Florida, Gainesville, FL 32610 0496, USA
    Value Health 11:389-99. 2008
  7. doi request reprint The cost of health care for children and adults with sickle cell disease
    Teresa L Kauf
    Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA
    Am J Hematol 84:323-7. 2009

Collaborators

Detail Information

Publications7

  1. pmc Patients' willingness to accept the risks and benefits of new treatments for chronic hepatitis C virus infection
    Teresa L Kauf
    Department of Pharmaceutical Outcomes and Policy, University of Florida, Gainesville, FL, USA
    Patient 5:265-78. 2012
    ..Some patients with chronic hepatitis C virus (HCV) infection forego treatment due to concerns about treatment efficacy, treatment duration, and side effects...
  2. pmc Factors influencing the participation of gastroenterologists and hepatologists in clinical research
    Anouk T Dev
    Duke Clinical Research Institute, PO Box 17969, Durham, North Carolina, USA
    BMC Health Serv Res 8:208. 2008
    ..We examined factors that influence the participation of gastroenterologists and hepatologists in clinical research...
  3. doi request reprint A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy
    Teresa L Kauf
    Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL 32610 0496, USA
    Value Health 11:1144-53. 2008
    ..The objective of this study was to examine the marginal impact of dosing, adverse events (AEs), and other factors on patients' health state utilities...
  4. doi request reprint Methodological concerns with economic evaluations of meningococcal vaccines
    Teresa L Kauf
    Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA
    Pharmacoeconomics 28:449-61. 2010
    ..Although comparisons across studies are difficult at best, recent work shows that incorporating the indirect benefits and costs of vaccination substantially improves cost effectiveness...
  5. doi request reprint Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV
    Teresa L Kauf
    University of Florida, Gainesville, Florida, USA
    Pharmacoeconomics 28:1025-39. 2010
    ..Genetic screening for HLA-B*5701 can identify patients who are likely to experience an HSR and reduces the incidence of the reaction...
  6. doi request reprint Cost-utility analysis of rimonabant in the treatment of obesity
    Christian Hampp
    Pharmacy Health Care Administration, College of Pharmacy, University of Florida, Gainesville, FL 32610 0496, USA
    Value Health 11:389-99. 2008
    ..To estimate the incremental cost-utility ratio (ICUR) of rimonabant 20 mg/day in the treatment of obesity from a third-party payer's perspective...
  7. doi request reprint The cost of health care for children and adults with sickle cell disease
    Teresa L Kauf
    Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA
    Am J Hematol 84:323-7. 2009
    ..Interventions designed to prevent SCD complications and avoid hospitalizations may reduce the significant economic burden of the disease...